Laboratório S. José foi adquirido pela SYNLAB
Os acionistas privados do Laboratório S. José venderam a empresa à SYNLAB.
Fundando há mais de 40 anos, o Laboratório S. José é um laboratório de analises clinicas em Portugal. O Laboratório oferece excelência na prestação de serviços, investindo constantemente em tecnologia, qualificação do capital humano e aprimoramento do relacionamento com clientes e parceiros.
A SYNLAB é um fornecedor international de diagnósticos médicos. Presente em mais de 40 países, a rede do grupo inclui mais de 400 laboratórios.
A equipa da Oaklins em Portugal assessorou o vendedor nesta transação.
Falar com a equipa da transação
Transações relacionadas
Lindenhofgruppe has sold its majority stake in LabPoint to Affidea Switzerland
LabPoint Medical Laboratories AG has been acquired by Affidea Switzerland AG. Through the transaction, Lindenhofgruppe AG gains a strong strategic partner to support the further development of LabPoint and will remain a shareholder with a reduced stake, continuing as a key customer of the company. It lays the foundation for LabPoint’s sustainable development under a new anchor shareholder, with the aim of further strengthening and selectively expanding its position in laboratory diagnostics.
Saber maisEuroHospital Varna has been acquired by Intermedica Group
EuroHospital Varna has been acquired by Intermedica Group, allowing the business to continue to grow and deliver high-quality healthcare services to its patients. Through the transaction, Intermedica Group expands its healthcare presence and intends to build a new model of integrated personalized care focused on preventive, holistic and digital medicine.
Saber maisOlyos Group has acquired a controlling stake in NewScience
Olyos Group has acquired a controlling stake in NewScience from its founders through a transaction structured in two stages, with the strategic objective of ultimately acquiring 100% of the company. The transaction forms part of NewScience’s international growth strategy and a gradual cash-out process for the founder, who intends to complete a full exit. Olyos intends to retain the management team through a put and call option mechanism and an earn-out linked to NewScience’s 2025 EBITDA.
Saber mais